Feed AZN
AZ

AstraZeneca

AZN · NYSE

$160.16 +0.32% (+$0.52)
1M +2.38%
Market Cap $247.4B
P/E Ratio 23.68x
Div. Yield 2.02%
ROE 21.75%

Bulios Fair Price

$154.82

3.3% downside

Trenutna cena

$160.16

Podcenjeno Poštena vrednost Precenjeno

Po podatkih Bulios Fair Price se delnica AZN trenutno trguje blizu svoje poštene vrednosti. Kako deluje?

Bulios Fair Price je ocena poštene vrednosti delnice iz Buliosovega modela vrednotenja. Je vhod za vašo lastno analizo, ne naložbeno priporočilo. Kako deluje?

Piotroski F-Score Strong
8/9
Valuation
53 /100
Fair
P/E 23.68x
EV/EBITDA 13.29x
P/S 4.03x
Growth
82 /100
Growing
EPS growth 45.80%
Rev. growth 9.82%
FCF growth 17.58%
Profitability
92 /100
Strong
Gross margin 81.88%
Net margin 17.02%
Op. margin 22.77%
Quality
76 /100
Excellent
ROIC 12.83%
ROE 21.75%
ROA 9.03%
Debt
69 /100
Low
Debt/Equity 0.64x
Current ratio 0.89x
Int. coverage 8.26x
Stability
46 /100
Moderate
Beta 0.21x
Rev. volatility 7.46%
EPS volatility 115.85%

Bulios Scoring opisuje kakovost in preteklost podjetja, ne prihodnjega donosa. Visok rezultat ni nakupni signal. Izvedite več

Vprašajte StockBota o AZN
Online

O podjetju

AstraZeneca (AZN) is a British-Swedish pharmaceutical company specializing in the research, development, and production of drugs for a wide range of therapeutic areas, including oncology, cardiovascular, respiratory, and immunological diseases. The company is known for its emphasis on scientific innovation and global healthcare initiatives, enabling it to bring new treatment options to patients worldwide. AstraZeneca also invests in the development of biologics and personalized medicine to improve treatment efficacy and outcomes. AstraZeneca (AZN) shares could be suitable for investors looking for opportunities in the pharmaceutical sector with a focus on research, innovation, and a broad therapeutic portfolio.

V vašem jeziku še ni na voljo, zato je besedilo v angleščini.

Sector

Healthcare

Industry

Drug Manufacturers - General

CEO

Pascal Claude Roland Soriot

Employees

96,100

Headquarters

Cambridge

Prihajajoči dogodki

30 OKT.

Earnings

Upcoming earnings report

47d

Uporabljamo nujne piškotke za delovanje spletnega mesta in izbirne analitične piškotke za merjenje uporabe. Preberite naš Pravilnik o zasebnosti.